Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. Spending Watchdog Rejects Avastin Again For Metastatic Colorectal Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche's offer of lump-sum payments to the NHS fails to sway NICE in its second draft evaluation of Avastin for the indication, but because it is not yet a final determination, stakeholders will have an opportunity to weigh in.

You may also be interested in...



UK Government Moves to Combat Low Uptake of Innovative Cancer Drugs

A report highlighting the low use of innovative cancer drugs in the U.K. has prompted the government to target more funding at this area. It may involve a shake-up of NICE, which the pharmaceutical industry has welcomed.

Erbitux and Avastin Aren’t Cost Effective, NICE Finds

Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel